Stocks News

LAST PRICE
52.0000
TODAY'S CHANGE (%)
Trending Down-2.7000 (-4.9360%)

Bid / Lots
51.9300/ 6
Ask / Lots
52.0400/ 6
Open / Previous Close
55.1400 / 54.7000
Day Range
Low 51.0500
High 55.1400
52 Week Range
Low 30.6800
High 110.2500
Volume
716,137
above average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Nov 13, 2024
- Cytokinetics Insider Sold Shares Worth $370,880, According to a Recent SEC Filing, from 7:10PM ET on Wednesday Nov 13, 2024 by MT Newswires
  7:10PM ET on Wednesday Nov 13, 2024 by MT Newswires
  Companies Mentioned: CYTK
  07:10 PM EST, 11/13/2024 (MT Newswires) -- Fady Ibraham Malik, EVP Research & Development, on November 12, 2024, sold 6,342 shares in Cytokinetics (CYTK) for $370,880. Following the Form 4 filing with the SEC, Malik has control over a total of 113,8...
Nov 12, 2024
- Cytokinetics to Participate in the 2024 Jefferies London Healthcare Conference, from 4:00PM ET on Tuesday Nov 12, 2024 by Dow Jones
  4:00PM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: CYTK
  
  Cytokinetics to Participate in the 2024 Jefferies London Healthcare Conference
  
  SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Company is scheduled to participate in a fireside chat at the 2024 Jefferies London Healthcare Conference on Tuesday, November 19, 2024 at 4:00 PM Greenwich Mean Time at The Waldorf Hilton Hotel in London, England.
Nov 11, 2024
- DJ Cytokinetics Price Target Maintained With a $120.00/Share by HC Wainwright & Co., from 11:10AM ET on Monday Nov 11, 2024 by Dow Jones
  11:10AM ET on Monday Nov 11, 2024 by Dow Jones
  Companies Mentioned: CYTK
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/CYTK/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 11, 2024 11:10 ET (16:10 GMT)
- Cytokinetics Doses First Participants in Study of Potential Muscular Dystrophy Treatment, from 7:57AM ET on Monday Nov 11, 2024 by MT Newswires
  7:57AM ET on Monday Nov 11, 2024 by MT Newswires
  Companies Mentioned: CYTK
  07:57 AM EST, 11/11/2024 (MT Newswires) -- Cytokinetics (CYTK) said Monday it has dosed the first participants in a phase 1 clinical study of CK-4015089 as a potential treatment for a specific type of muscular dystrophy and other impaired muscle con...
- Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4015089, from 7:30AM ET on Monday Nov 11, 2024 by Dow Jones
  7:30AM ET on Monday Nov 11, 2024 by Dow Jones
  Companies Mentioned: CYTK
  
  Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4015089
  
  Advancement of Fast Skeletal Muscle Troponin Activator Expands Pipeline of Muscle-Directed Drug Candidates

Yesterday
- Viking Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Viking Therapeutics, Inc. (VKTX), from 18 hours ago by Dow Jones
  18 hours ago by Dow Jones
  Companies Mentioned: VKTX
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX, from 19 hours ago by Dow Jones
  19 hours ago by Dow Jones
  Companies Mentioned: VKTX
- VKTX ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Viking Therapeutics, Inc. Shareholders Who Lost Money, from 7:31AM ET on Thursday Nov 14, 2024 by Dow Jones
  7:31AM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: VKTX
Nov 13, 2024
- DJ Avidity Biosciences Is Maintained at Buy by Chardan Capital, from 6:40PM ET on Wednesday Nov 13, 2024 by Dow Jones
  6:40PM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: RNA
- DJ Nuvalent Is Maintained at Outperform by BMO Capital, from 8:14AM ET on Wednesday Nov 13, 2024 by Dow Jones
  8:14AM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: NUVL
- DJ Avidity Biosciences Price Target Maintained With a $60.00/Share by Needham, from 5:07AM ET on Wednesday Nov 13, 2024 by Dow Jones
  5:07AM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: RNA
Nov 12, 2024
- Viking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting(R) 2024, from 4:05PM ET on Tuesday Nov 12, 2024 by PR Newswire
  4:05PM ET on Tuesday Nov 12, 2024 by PR Newswire
  Companies Mentioned: VKTX
- Viking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting(R) 2024, from 4:05PM ET on Tuesday Nov 12, 2024 by Dow Jones
  4:05PM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: VKTX
- Lost Money on Viking Therapeutics, Inc. (VKTX)? Contact Levi & Korsinsky Regarding an Ongoing Investigation, from 3:47PM ET on Tuesday Nov 12, 2024 by Dow Jones
  3:47PM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: VKTX
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX, from 2:31PM ET on Tuesday Nov 12, 2024 by Dow Jones
  2:31PM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: VKTX

Cytokinetics Inc
NASDAQ:CYTKUnited States

Search Criteria

Nov 13, 2024

Cytokinetics Insider Sold Shares Worth $370,880, According to a Recent SEC Filing, from 7:10PM ET on Wednesday Nov 13, 2024 by MT Newswires

Nov 12, 2024

Cytokinetics to Participate in the 2024 Jefferies London Healthcare Conference, from 4:00PM ET on Tuesday Nov 12, 2024 by Dow Jones

Nov 11, 2024

DJ Cytokinetics Price Target Maintained With a $120.00/Share by HC Wainwright & Co., from 11:10AM ET on Monday Nov 11, 2024 by Dow Jones

Cytokinetics Doses First Participants in Study of Potential Muscular Dystrophy Treatment, from 7:57AM ET on Monday Nov 11, 2024 by MT Newswires

Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4015089, from 7:30AM ET on Monday Nov 11, 2024 by Dow Jones

Peers Headlines

Yesterday

Viking Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Viking Therapeutics, Inc. (VKTX), from 18 hours ago by Dow Jones

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX, from 19 hours ago by Dow Jones

VKTX ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Viking Therapeutics, Inc. Shareholders Who Lost Money, from 7:31AM ET on Thursday Nov 14, 2024 by Dow Jones

Nov 13, 2024

DJ Avidity Biosciences Is Maintained at Buy by Chardan Capital, from 6:40PM ET on Wednesday Nov 13, 2024 by Dow Jones

DJ Nuvalent Is Maintained at Outperform by BMO Capital, from 8:14AM ET on Wednesday Nov 13, 2024 by Dow Jones

DJ Avidity Biosciences Price Target Maintained With a $60.00/Share by Needham, from 5:07AM ET on Wednesday Nov 13, 2024 by Dow Jones

Nov 12, 2024

Viking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting(R) 2024, from 4:05PM ET on Tuesday Nov 12, 2024 by PR Newswire

Viking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting(R) 2024, from 4:05PM ET on Tuesday Nov 12, 2024 by Dow Jones

Lost Money on Viking Therapeutics, Inc. (VKTX)? Contact Levi & Korsinsky Regarding an Ongoing Investigation, from 3:47PM ET on Tuesday Nov 12, 2024 by Dow Jones

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX, from 2:31PM ET on Tuesday Nov 12, 2024 by Dow Jones